Biomay Expands DNA Manufacturing Portfolio with Cell-free Enzymatic DNA Synthesis
(October 26, 2026) New technology complements Biomay’s established plasmid DNA manufacturing capabilities. As the result of focused internal research and development, the company has filed a patent application earlier this year. Biomay is now implementing the technology for GMP manufacturing, with the first GMP batches completed by end of this year.
> More infoBiomay Launches Fast-track Manufacturing for Personalized mRNA and DNA Cancer Vaccines
(October 21, 2026) Biomay highlights its dedicated manufacturing platform for neoantigen-based cancer vaccines. Designed for the demanding timelines of individualized cancer immunotherapies, it enables the production of personalized DNA cancer vaccines in as little as two weeks and mRNA-based vaccines in approximately three weeks from starting material to release.
> More infoSynthego and Biomay Collaborate to Accelerate Access to mRNA manufacturing and CRISPR Solutions
(October 1st, 2026) Synthego, a leading provider of CRISPR solutions, and Biomay, a CDMO specializing in mRNA manufacturing, LNP formulation, aseptic fill-finish, plasmid DNA, and recombinant proteins, today announced a non-exclusive collaboration to market, promote, and resell Biomay products and services to Synthego customers in North America.
> More infoBiomay Distributes Lentivirus Starting Plasmids Off-the Shelf
(March 3rd, 2025) Lentivirus starting plasmids are Biomay’s most recent off-the-shelf offering, as the company announced. The set of pre-manufactured lentiviral plasmids are designated for the manufacture of recombinant lentiviral gene transfer vectors.
The offered DNA plasmids are immediately available in “RUO” (research use only) quality, whereas GMP-grade lentiviral plasmids will be offered in a few months …
Biomay Offers AAV Starting Plasmids in GMP and Research Quality – Off-the Shelf
(October 17th, 2024) Biomay now offers ready-made starting plasmids for the manufacture of recombinant adeno-associated virus (rAAV) vectors.
The offered DNA plasmids are immediately available in the quality grades “RUO” and “GMP”. The new catalog products are available off-the-shelf and distributed via Biomay‘s webshop …
> More infoAreterna and Biomay Announce Strategic Partnership to Jointly Serve mRNA CDMO Customers in Europe and North America
(September 18th, 2024) Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials, announced it has entered a strategic partnership with Biomay, a seasoned CDMO that offers GMP manufacturing of mRNA, plasmid DNA and recombinant proteins …
> More infoBiomay Announces Expansion of its GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
(October 2023) Biomay, a Vienna based biotech manufacturer, announced a facility extension and is now able to expand its GMP-facilities, to offer mRNA manufacturing and aseptic filling services.
> More info